FDA reverses course on Moderna's flu vaccine review

Good morning, healthcare professional.

The FDA reversed its refusal of Moderna's flu vaccine application while proposing single pivotal trials as the new approval standard. Compass Pathways submitted its psilocybin therapy application, and Grail's multi-cancer screening test disappointed in a key study.

These shifts affect how medicines reach patients, from evidentiary standards to regulatory consistency. For clinicians managing treatment options and trials, grasping these changes matters now more than ever.

In today's healthcare digest:

• FDA reverses Moderna mRNA flu vaccine decision, signaling instability
• Agency proposes one pivotal trial as new approval standard
• Compass Pathways advances psilocybin therapy toward FDA approval
• Grail's Galleri multi-cancer blood test fails pivotal study

FDA Reverses Course on Moderna Flu Vaccine in Unusual Turnaround

The FDA agreed to review Moderna's mRNA flu vaccine application after initially refusing it, marking an extraordinary about-face. The reversal comes amid broader criticism of chaos and inconsistency under new leadership.

Unpacked:

• The initial refusal was unusual, but reversing within days represents unprecedented flip-flopping that undermines industry confidence.
• A former Moderna executive expressed dismay that COVID-19 era innovation and partnership have been lost to uncertainty.
• The incident exemplifies signs of chaos, raising questions about consistent pathways for innovative therapies.

FDA Leaders Propose Major Shift to Single Pivotal Trial Standard

FDA leaders announced a policy shift proposing one pivotal trial, rather than two, as the default approval requirement. This represents a fundamental change that could accelerate timelines and reduce costs.

Unpacked:

• The shift from two trials to one represents a significant change, potentially cutting years and hundreds of millions from development programs.
• The change signals faster treatment access, though critics may question whether single trials provide sufficient evidence across diverse populations.
• This announcement joins broader streamlining efforts, though timing alongside the Moderna reversal raises questions about consistency and rationale.

Psychedelic Therapy Advances as Compass Submits Psilocybin Application

Psychedelic therapy stocks surged as Compass Pathways moved forward with its FDA submission for psilocybin treatment. However, concerns are emerging about ensuring quality as the field commercializes.

Unpacked:

• Compass Pathways' submission represents the first major psilocybin application, potentially opening doors for a new psychiatric medication class.
• The market reacted swiftly, with investors celebrating the milestone and stocks rallying, reflecting significant financial interest.
• A 2012 trial participant expressed alarm, emphasizing that effective therapy requires support beyond administering the drug.

Grail's Multi-Cancer Blood Test Fails Key Study in Major Setback

Grail's Galleri multi-cancer detection blood test failed to meet expectations in a pivotal study. The failure raises questions about multi-cancer screening viability.

Unpacked:

• Grail has been one of the most prominent liquid biopsy companies, making this failure particularly significant for investor confidence.
• The Galleri test was designed to detect multiple cancers from a single blood draw, an ambitious approach now facing validity questions.
• This setback could impact the broader liquid biopsy field, potentially affecting funding, pathways, and adoption timelines for similar approaches.

The Shortlist

• Hims & Hers announced plans to acquire Eucalyptus as the telehealth company looks to expand its footprint internationally.

• Johnson & Johnson outlined a $1 billion cell therapy plant and 500 new jobs in Pennsylvania as part of its U.S. investment plan.

• Eli Lilly reported another trial win for the Zepbound-Taltz combination in psoriasis and obesity, aiming to break down treatment silos.

• Bristol Myers Squibb received FDA acceptance for its protein degrader application, advancing the novel therapeutic modality toward potential approval.

• Korsana Biosciences emerged with $175 million in venture backing to advance an Alzheimer's antibody therapy using brain shuttle technology.